Literature DB >> 32238781

ABCA3 mutations in adult pulmonary fibrosis patients: a case series and review of literature.

Dymph Klay1, Mark G J P Platenburg1, Rein H N A J van Rijswijk2, Jan C Grutters1,3, Coline H M van Moorsel1,3.   

Abstract

PURPOSE OF REVIEW: The current review aims to recognize the variability in clinical presentation of adult patients with bi-allelic ABCA3 mutations, create more depth in ABCA3 mutations reported and highlight the influence of environmental factors on disease course. RECENT
FINDINGS: Mutations in ABCA3 are predominantly linked to neonatal and pediatric interstitial lung disease (ILD) with a minority surviving beyond puberty. Here, we present three patients with ABCA3 mutations who present with disease at the age of 19, 61 and 77. Moreover, we identified c.4451G>C (p.R1484P), c.1675G>A (p.G559R) and c.4745C>G (p.T1582S) as three novel ABCA3 mutations. In addition, we identified six additional patients with ABCA3 mutations in literature who reached an age above 18. Furthermore, we discuss the influence of infections, drugs and smoking on disease course.
SUMMARY: Although extremely rare, patients with bi-allelic mutations in ABCA3 may present at adulthood. Late onset of disease may be influenced by type of mutation or environmental factors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32238781     DOI: 10.1097/MCP.0000000000000680

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  ABCA3 mutations in adults with interstitial lung disease: is there a link?

Authors:  Ramcés Falfán-Valencia
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

2.  The clinical course of interstitial lung disease in an adult patient with an ABCA3 homozygous complex allele under hydroxychloroquine and a review of the literature.

Authors:  Marie Legendre; Xavier Darde; Marion Ferreira; Sandra Chantot-Bastaraud; Marion Campana; Laurent Plantier; Nadia Nathan; Serge Amselem; Annick Toutain; Patrice Diot; Sylvain Marchand-Adam
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

3.  Biologic characterization of ABCA3 variants in lung tissue from infants and children with ABCA3 deficiency.

Authors:  Kathryn K Xu; Daniel J Wegner; Lucille C Geurts; Hillary B Heins; Ping Yang; Aaron Hamvas; Pirooz Eghtesady; Stuart C Sweet; F Sessions Cole; Jennifer A Wambach
Journal:  Pediatr Pulmonol       Date:  2022-03-17

4.  Three Infants with Pathogenic Variants in the ABCA3 Gene: Presentation, Treatment, and Clinical Course.

Authors:  Xin Si; Lea C Steffes; Jennifer C Schymick; Florette K Hazard; Michael C Tracy; David N Cornfield
Journal:  J Pediatr       Date:  2020-12-24       Impact factor: 4.406

Review 5.  Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction.

Authors:  Ashley L Cooney; Jennifer A Wambach; Patrick L Sinn; Paul B McCray
Journal:  Front Genome Ed       Date:  2022-01-14

6.  First Steps toward Personalized Therapies for ABCA3 Deficiency.

Authors:  Jennifer A Wambach; Lawrence M Nogee; F Sessions Cole
Journal:  Am J Respir Cell Mol Biol       Date:  2022-04       Impact factor: 7.748

7.  Case Report: Report of Two Cases of Interstitial Lung Disease Caused by Novel Compound Heterozygous Variants in the ABCA3 Gene.

Authors:  Fang Chen; Zhiwei Xie; Victor Wei Zhang; Chen Chen; Huifeng Fan; Dongwei Zhang; Wenhui Jiang; Chunli Wang; Peiqiong Wu
Journal:  Front Genet       Date:  2022-04-06       Impact factor: 4.772

8.  Identification and immune characteristics of molecular subtypes related to fatty acid metabolism in idiopathic pulmonary fibrosis.

Authors:  Fan Yang; Zhaotian Ma; Wanyang Li; Jingwei Kong; Yuhan Zong; Bilige Wendusu; Qinglu Wu; Yao Li; Guangda Dong; Xiaoshan Zhao; Ji Wang
Journal:  Front Nutr       Date:  2022-09-23

9.  Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases.

Authors:  Matthias Griese
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.